Medicina intensiva
-
Practice Guideline
[Monitoring pain: recommendations of the Analgesia and Sedation Work Group of SEMICYUC].
In critically ill patients, pain is frequently underestimated and so insufficiently managed. Psychological, haemodynamic and neuroendocrine responses, secondary to untreated pain, could produce morbidity and even increases in patient mortality. All members of the intensive care team must have abilities to assess and to manage pain. ⋯ Adequate and regular patient assessment leads to improved pain control. Scores higher than 3 points should not be permitted. A pain-free Intensive Care Unit should be a quality standard healthcare aim.
-
Letter Case Reports
[Meningococcal sepsis associated to ST segment and cardiac enzymes elevation].
-
Health care interventions entail a risk of adverse events (AE), that may cause lesions, incapacities and even death in the patients. Given the complexity of the care of the critical patient, the Critical Care Services are a high risk setting for the appearance of AE in these patients, many of them avoidable. ⋯ The voluntary and anonymous registry and reporting systems make it possible to identify a significant percentage of these incidents, analyze the factors related (that contribute or limit), establish preventive strategies, permitting management of risk, and potentially reduce the appearance and consequences of avoidable AE with all this. Initiatives such as the ICU Safety Reporting System (ICUSRS), that use a web database as registry system and includes contributions from different sites, favor the safety and risk culture, essential in the improvement of health quality of critical patients.
-
Case Reports
[Use of methylene blue in the treatment of vasoplegic syndrome of post-operative heart surgery].
Vasoplegia is a frequent complication in post-operative heart surgery and determines a significant increase in morbidity-mortality. When vasoplegia persists in spite of optimized fluid therapy with the use of Swan-Ganz catheter, we have a safe, effective and economical alternative, methylene blue. ⋯ The use of a single dose of methylene blue resolved the hemodynamic instability and allowed for total discontinuation of vasoactive drugs. Thus, we present this new indication of methylene blue, still not approved by the corresponding bodies, for which no national publications have been found and its clinical management and the absence of adverse effects after its use.